Evidence map›Paper›PMID 39192162›Full record

Trial reportInflammopharmacology2024

Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study.

Mostafa M Bahaa, Sahar K Hegazy, Maha M Maher, Monir M Bahgat, Sahar M El-Haggar

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05558761 (Clinical Study to Evaluate the Possible Efficacy of Pentoxifylline in Patients With Ulcerative Colitis Treated With Mesalamine), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05558761 phase2completednot on this map

Clinical Study to Evaluate the Possible Efficacy of Pentoxifylline in Patients With Ulcerative Colitis Treated With Mesalamine

TypeinterventionalSponsorTanta UniversityRan2022 to 2024Enrolled50ConditionsInflammatory Bowel DiseasesArmsPentoxifylline 400 MG
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mostafa M BahaaPharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt. mostafabahaamnf@gmail.com.ORCID http://orcid.org/0000-0003-3332-4573
Sahar K HegazyClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.
Maha M MaherInternal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Monir M BahgatInternal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Sahar M El-HaggarClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUlcerative colitis (UC) is an inflammatory bowel disease (IBD) that lasts a long time and has a variety of causes.

aimThe primary aim of this study was to evaluate pentoxifylline's (PTX) essential function in patients with UC.

methodsFifty-two mild to moderate UC patients who matched the eligibility requirements participated in this clinical study. One gram of mesalamine (t.i.d.) and a placebo were administered to the mesalamine group (n = 26) for a duration of 24 weeks. Mesalamine 1 g t.i.d. and PTX 400 mg two times daily were administered to the PTX group (n = 26) for 24 weeks. A gastroenterologist investigated patients at the start and 6 months after the medication was given to assess disease activity index (DAI) and numeric pain rating scale (NRS). Also, interleukin-6 (IL-6), sphingosine 1 phosphate (S1P), tumor necrosis factor-alpha (TNF-α), and fecal myeloperoxidase (MPO) were measured before and after therapy. Zonula occuldin-1 (ZO-1) and signal transducer and activator of transcription factor-3 (STAT-3) expression was assessed before and after therapy as well as histological assessment. Short Form 36 Health Survey (SF-36), was assessed for each patient before and after 6 months of treatment.

resultsThe PTX group showed statistically lower levels of serum SIP, TNF-α, IL-6, faecal MPO, gene expression of STAT-3, and a significant increase of ZO-1 in comparison with the mesalamine group. DAI and NRS significantly decreased whereas SF-36 significantly increased in the PTX group.

conclusionPTX could alleviate inflammation in patients with UC, so it might be promising adjunctive for patients with UC. TRIAL REGISTRATION IDENTIFIER: NCT05558761.

Indexed as

Colitis, UlcerativeInterleukin-6MesalaminePentoxifyllineSTAT3 Transcription FactorZonula Occludens-1 ProteinAdultAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodFemaleHumansLysophospholipidsMaleMiddle AgedSignal TransductionAnti-Inflammatory Agents, Non-SteroidalIL6 protein, humanInterleukin-6LysophospholipidsMesalaminePentoxifyllineSTAT3 protein, humanSTAT3 Transcription FactorTJP1 protein, humanZonula Occludens-1 ProteinIL-6/STAT-3PTXUlcerative colitisZonula occulden 1

Identifiers

PMID39192162

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.